
    
      The phase 2 single arm study will assess efficacy of AMG 337 (based on confirmed ORR) in
      subjects with advanced or metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene
      fusion, as determined by fluorescent in situ hybridization (FISH) or other diagnostic methods
      and confirmed by RNA sequencing (RNAseq).
    
  